- Prometheus Biosciences (NASDAQ:RXDX) has received a $10M milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize the company's second program, PR600.
- Prometheus has selected a clinical candidate for PR600, targeting an undisclosed member of the tumor-necrosis factor superfamily for the treatment of inflammatory bowel disease (IBD) and is initiating IND-enabling studies.
- The company said that it expects to file an Investigational New Drug Application for PR600 in the third quarter of 2022 and plans to explore its utility in other immune-mediated indications beyond IBD.